Rezension:

I'm on work experience Diltiazem Cardizem Drugmaker Retrophin Inc said it offered to buy therest of Transcept Pharmaceuticals shares it does not already ownfor $4 per share, valuing Transcept at about $75 million.Retrophin's offer represents an 11 percent premium toTranscept's closing share price of $3.59 on the Nasdaq onWednesday.

Bewertung: